Back to All Events

Endocrinologic Drugs Advisory Committee

  • IQVIA Solutions Denmark A/S Denmark (map)

On Wednesday, June 28, 2023, the Endocrinologic Drugs Advisory Committee will discuss new drug application (NDA-215559), for Palovarotene capsules, submitted by Ipsen Biopharmaceuticals, Inc. The proposed indication is the prevention of heterotopic ossification in adults and children (females aged 8 years and above and males 10 years and above) with fibrodysplasia ossificans progressive (FOP).

 

Source:: https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-28-2023-meeting-endocrinologic-drugs-advisory-committee-meeting-announcement-06282023#event-materials
Earlier Event: June 15
Vaccines and Related Biological Products Advisory Committee (VRBPAC)
Later Event: September 13
Cardiovascular and Renal Drugs Advisory Committee